Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Blood (2023) 142 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2023-187687

Published: 2023

Journal Articles

Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

Blood (2023) 142 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2023-190808

Published: 2023

Journal Articles

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Blood (2023) 142 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2023-187156

Published: 2023

Journal Articles

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Blood (2023) 142 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2023-187728

Published: 2023

Journal Articles

Care Patterns and Barriers to Outpatient Care for Adults with Acute Myeloid Leukemia (AML) Following Intensive Chemotherapy at National Comprehensive Cancer Network (NCCN) Institutions

Anna B. Halpern, Jessica M Sugalski, Lindsey Bandini, F. Marc Stewart, Roland B. Walter

Blood (2023) 142 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2023-174568

Published: 2023

Journal Articles

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2023-187460

Published: 2023

Journal Articles

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Blood (2023) 142 (Supplement 1): 4896.

https://doi.org/10.1182/blood-2023-187909

Published: 2023

Journal Articles

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

Thomas C. Shea, MD, Jeffrey Johnston, MA, William Walsh, MD, Sherif Farag, MD, PhD, John McCarty, MD, Asad Bashey, MD, PhD, Luis Isola, MD, Marc Stewart, MD, Michael Kelly, MA, Kouros Owzar, PhD, Charles Linker, MD

Blood (2007) 110 (11): 486.

https://doi.org/10.1182/blood.V110.11.486.486

Published: 2007

Journal Articles

In Vivo Chemotherapy Protection and Efficacy of Multidrug Resistance (MDR-1) Gene Transfer in a Patient with Refractory Non-Hodgkin’s Lymphoma (NHL).

Pamela S. Becker, MD, PhD, Adrianne N. Hanks, BA, Ying Ping Yu, MD, Ann Marie Ceredona, MT(ASCP), MA, William V. Walsh, MD, Judith L. O’Donnell, BS, Christopher Baum, MD, Lynn Kallander, MT(ASCP), BS, Philip A. Lowry, MD, T.J. Fitzgerald, MD, Peter Westervelt, MD, PhD, F. Marc Stewart, MD

Blood (2005) 106 (11): 3054.

https://doi.org/10.1182/blood.V106.11.3054.3054

Published: 2005

Journal Articles

Transfer of the Multidrug Resistance Gene, MDR-1, to Hematopoietic Progenitors from a Patient with Transformed Large Cell Lymphoma, and Demonstration of In Vivo Chemotherapy Protection with Dose Escalating Chemotherapy.

Pamela S. Becker, MD, PhD, Ying Ping Yu, MD, Ann Marie Ceredona, MT, MA, William V. Walsh, MD, Judith L. O’Donnell, BS, RN, Christopher Baum, MD, Lynn Kallander, BS, Philip A. Lowry, MD, T. J. Fitzgerald, MD, Peter Westervelt, MD, PhD, F. Marc Stewart, MD

Blood (2004) 104 (11): 5278.

https://doi.org/10.1182/blood.V104.11.5278.5278

Published: 2004

Journal Articles

Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy

Karen K. Ballen, Pamela S. Becker, Robert V. B. Emmons, Thomas J. Fitzgerald, Chung C. Hsieh, Qin Liu, Christine Heyes, Yeteive Clark, William Levy, Jean Francois Lambert, Frank Chiafari, Irma Szymanski, Sarah Rososhansky, Mark A. Popovsky, F. Marc Stewart, Peter J. Quesenberry

Blood (2002) 100 (2): 442–450.

https://doi.org/10.1182/blood.V100.2.442

Published: 2002

Journal Articles

Host marrow stem cell potential and engraftability at varying times after low-dose whole-body irradiation

F. Marc Stewart, Suju Zhong, Jean-François Lambert, Gerald A. Colvin, Mehrdad Abedi, Mark S. Dooner, Christina I. McAuliffe, Han Wang, Chung Hsieh, Peter J. Quesenberry

Blood (2001) 98 (4): 1246–1251.

https://doi.org/10.1182/blood.V98.4.1246

Published: 2001

Journal Articles

Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice

Peter J. Quesenberry, Suju Zhong, Han Wang, Marc Stewart

Blood (2001) 97 (2): 557–564.

https://doi.org/10.1182/blood.V97.2.557

Published: 2001

Journal Articles

Cytokine-Facilitated Transduction Leads to Low-Level Engraftment in Nonablated Hosts

Ellen L.W. Kittler, Stefan O. Peters, Rowena B. Crittenden, Michelle E. Debatis, Hayley S. Ramshaw, F. Marc Stewart, Peter J. Quesenberry

Blood (1997) 90 (2): 865–872.

https://doi.org/10.1182/blood.V90.2.865

Published: 1997

NARROW

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Care Patterns and Barriers to Outpatient Care for Adults with Acute Myeloid Leukemia (AML) Following Intensive Chemotherapy at National Comprehensive Cancer Network (NCCN) Institutions

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

In Vivo Chemotherapy Protection and Efficacy of Multidrug Resistance (MDR-1) Gene Transfer in a Patient with Refractory Non-Hodgkin’s Lymphoma (NHL).

Transfer of the Multidrug Resistance Gene, MDR-1, to Hematopoietic Progenitors from a Patient with Transformed Large Cell Lymphoma, and Demonstration of In Vivo Chemotherapy Protection with Dose Escalating Chemotherapy.

Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy

Host marrow stem cell potential and engraftability at varying times after low-dose whole-body irradiation

Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice

Cytokine-Facilitated Transduction Leads to Low-Level Engraftment in Nonablated Hosts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only